Sensei Biotherapeutics (SNSE)
Nasdaq Market Closed
Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted cancer therapies. Its work sits within oncology drug development, where companies seek to improve outcomes by attacking the biological pathways that allow tumors to grow, survive, and evade treatment. As a clinical-stage business, Sensei does not operate like a commercial pharmaceutical company with a broad portfolio of marketed medicines; its value is primarily tied to the progress, safety profile, and therapeutic potential of its investigational pipeline.
The company’s lead program, PIKTOR, is designed as an oral combination therapy aimed at multiple nodes of the PI3K/AKT/mTOR pathway. This pathway is an important signaling network involved in cell growth, metabolism, and survival, and it is frequently implicated in cancer. By targeting more than one point in the pathway, the program is intended to address oncogenic signaling in a more comprehensive way than a single-node approach. PIKTOR is being evaluated for potential use in endometrial and breast cancers, two areas where biomarker-driven and pathway-focused treatments remain important areas of research.
Beyond its lead asset, Sensei is advancing additional programs that focus on tumor metabolism and cancer signaling. These research areas reflect a broader strategy of identifying vulnerabilities that are essential to tumor biology. Investors typically assess the company through clinical milestones, regulatory updates, trial data, financing capacity, and the competitiveness of its target indications. Sensei’s profile is therefore closely linked to the high-risk, high-reward nature of biotechnology innovation in oncology.
Last updated
- Market Cap
- 21.27M
- P/E
- —
- P/FCF
- —
- P/S
- —
- Enterprise Value
- -131.04M
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Address
- 1405 RESEARCH BLVD, SUITE 125, ROCKVILLE, MD, 20850
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025
VISTA Inhibitor Clinical Trials Drug Approval Insight - GlobeNewswire
Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101
Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting
Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment
Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium
Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences
Sensei Biotherapeutics to Present at Upcoming Conferences
Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones
Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting
Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer
Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting
Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023
Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®
Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 21.27M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- -131.04M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- -0.15
- P/S
P/S ratio compares a company's share price to its revenue per share.
- —
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 0.71
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- —
- EPS
- -137.46
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -24.11M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 134.36%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -89.81%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 14.39
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 14.39
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 10.73
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 35.3K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 15.85
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -170.63M | -4.96M | -4.85M | -5.21M | -7.27M |
| EBITDA | -170.6M | -4.91M | -4.82M | -5.18M | -7.24M |
| Net income | -170.24M | -4.72M | -4.57M | -4.94M | -6.86M |
| Basic EPS | -131.45 | -3.74 | -3.62 | -3.91 | -5.45 |
| Diluted EPS | -131.45 | -3.74 | -3.62 | -3.91 | -5.45 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 205.38M | 22.9M | 27.59M | 31.78M | 38.27M |
| Total liabilities | 14.19M | 4.31M | 4.58M | 4.47M | 6.29M |
| Total equity | -137.29M | 18.59M | 23.01M | 27.31M | 31.99M |
| Cash & equivalents | 152.33M | 8.67M | 10.56M | 12.56M | 9.88M |
| Current assets | 204.23M | 21.51M | 25.79M | 29.57M | 35.68M |
| Current liabilities | 14.19M | 4.25M | 4.44M | 3.87M | 5.23M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -10.73M | -3.86M | -3.59M | -5.91M | -7.09M |
| Investing cash flow | -31.44M | 2.08M | 1.74M | 8.76M | 7.19M |
| Financing cash flow | 185.83M | -111K | -152K | -168K | -214K |
| Change in cash | 143.66M | -1.89M | -2M | 2.68M | -117K |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | S-3/A — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | 10-K/A — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | 4 — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | 4 — Sensei Biotherapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Peyer James | View Filing | |
| form 4 | Form 4 — Peyer James | View Filing | |
| form 4 | Form 4 — Cambrian BioPharma Inc | View Filing | |
| form 4 | Form 4 — Cambrian BioPharma Inc | View Filing | |
| edgar index | 8-K — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | DEFA14A — Sensei Biotherapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | DEFA14A — Sensei Biotherapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | 3 — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | 4 — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | 4 — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | 4 — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | 8-K — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | 10-Q — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | S-8 — Sensei Biotherapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 3 | Form 3 — ICS OPPORTUNITIES II LLC | View Filing | |
| form 3 | Form 3 — ENGLANDER ISRAEL A | View Filing | |
| form 3 | Form 3 — MILLENNIUM GROUP MANAGEMENT LLC | View Filing | |
| form 3 | Form 3 — MILLENNIUM MANAGEMENT LLC | View Filing | |
| edgar index | 144 — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | S-3 — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | DEF 14A — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | DEFA14A — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | ARS — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | PRE 14A — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | 8-K — Sensei Biotherapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K/A — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | 4 — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | 4 — Sensei Biotherapeutics, Inc. | View Filing | |
| form 4 | Form 4 — MILLENNIUM MANAGEMENT LLC | View Filing | |
| form 4 | Form 4 — ENGLANDER ISRAEL A | View Filing | |
| form 4 | Form 4 — MILLENNIUM MANAGEMENT LLC | View Filing | |
| form 4 | Form 4 — MILLENNIUM MANAGEMENT LLC | View Filing | |
| form 4 | Form 4 — ENGLANDER ISRAEL A | View Filing | |
| form 4 | Form 4 — MILLENNIUM MANAGEMENT LLC | View Filing | |
| form 4 | Form 4 — MILLENNIUM GROUP MANAGEMENT LLC | View Filing | |
| form 4 | Form 4 — ICS OPPORTUNITIES II LLC | View Filing | |
| form 4 | Form 4 — ENGLANDER ISRAEL A | View Filing | |
| form 4 | Form 4 — ENGLANDER ISRAEL A | View Filing | |
| form 4 | Form 4 — MILLENNIUM MANAGEMENT LLC | View Filing | |
| form 4 | Form 4 — MILLENNIUM GROUP MANAGEMENT LLC | View Filing | |
| form 4 | Form 4 — ICS OPPORTUNITIES II LLC | View Filing | |
| form 4 | Form 4 — MILLENNIUM GROUP MANAGEMENT LLC | View Filing | |
| form 4 | Form 4 — ICS OPPORTUNITIES II LLC | View Filing | |
| form 4 | Form 4 — MILLENNIUM MANAGEMENT LLC | View Filing | |
| form 4 | Form 4 — ENGLANDER ISRAEL A | View Filing | |
| form 4 | Form 4 — MILLENNIUM GROUP MANAGEMENT LLC | View Filing | |
| form 4 | Form 4 — ICS OPPORTUNITIES II LLC | View Filing | |
| form 4 | Form 4 — MILLENNIUM MANAGEMENT LLC | View Filing | |
| form 4 | Form 4 — MILLENNIUM GROUP MANAGEMENT LLC | View Filing | |
| form 4 | Form 4 — ICS OPPORTUNITIES II LLC | View Filing | |
| form 4 | Form 4 — MILLENNIUM MANAGEMENT LLC | View Filing | |
| form 4 | Form 4 — ENGLANDER ISRAEL A | View Filing | |
| form 4 | Form 4 — MILLENNIUM GROUP MANAGEMENT LLC | View Filing | |
| form 4 | Form 4 — ICS OPPORTUNITIES II LLC | View Filing | |
| form 4 | Form 4 — MILLENNIUM MANAGEMENT LLC | View Filing | |
| form 4 | Form 4 — MILLENNIUM MANAGEMENT LLC | View Filing | |
| form 4 | Form 4 — ENGLANDER ISRAEL A | View Filing | |
| form 4 | Form 4 — ENGLANDER ISRAEL A | View Filing | |
| form 4 | Form 4 — MILLENNIUM GROUP MANAGEMENT LLC | View Filing | |
| form 4 | Form 4 — ICS OPPORTUNITIES II LLC | View Filing | |
| form 4 | Form 4 — MILLENNIUM MANAGEMENT LLC | View Filing | |
| form 4 | Form 4 — ENGLANDER ISRAEL A | View Filing | |
| form 4 | Form 4 — MILLENNIUM GROUP MANAGEMENT LLC | View Filing |